Table 1.
Baseline characteristics of vitiligo patients and controls.
| Variables | Vitiligo=63 | Controls=63 | p-value |
|---|---|---|---|
| Age (years), mean ± SD | 38.7 ± 14.0 | 39.9 ± 11.6 | 0.604 |
| Gender, n (%) | 0.476 | ||
| Female | 34 (54.0%) | 30 (47.6%) | |
| Male | 29 (46.0%) | 33 (52.4%) | |
| BMI (kg/m2), mean ± SD | 27.6 ± 7.4 | 30.6 ± 5.7 | 0.012 [S] |
| Smoking, n (%) | 0.180 | ||
| Active | 9 (14.3%) | 6 (9.5%) | |
| Non-smoker | 20 (31.7%) | 32 (50.8%) | |
| Ex-smoker | 8 (12.7%) | 7 (11.1%) | |
| Passive | 26 (41.3%) | 18 (28.6%) | |
| Vitiligo duration, mean ± SD, range | 13.3 ± 12.7, (0.5–64) | ||
| Vitiligo types, n (%) | |||
| Vulgaris | 45 (71.4%) | ||
| Universal | 9 (14.3%) | ||
| Focal | 7 (11.1%) | ||
| Acrofacial | 2 (3.2%) | ||
| BSA (%), mean ± SD | 31.4 ± 32.5 | ||
| Therapy, n (%) | |||
| Topical steroids | 52 (82.5%) | ||
| Phototherapy | 22 (34.9%) | ||
| Immune therapy (TCI) | 39 (61.9%) | ||
| Depigmentation | 5 (7.9%) |
Values are means ± SD or numbers and percentages. BMI, Body mass index; kg, kilogram; m2, meter square; S, significant; n, number; P value, probability value (<0.05). TCI, Topical calcineurin inhibitors.